Compared with alendronate, teriparatide was associated with significantly greater pain reduction and better quality of life among postmenopausal women with osteoporosis. Teriparatide has a ...
Background: This paper presents the model and results to evaluate the use of teriparatide as a first-line treatment of severe postmenopausal osteoporosis (PMO) and Glucocorticoid-induced ...
Teriparatide (recombinant) 250mcg/mL; soln for SC inj; contains m-cresol. Teriparatide stimulates new bone formation on trabecular and cortical (periosteal and/or endosteal) bone surfaces by ...
Until now, the main options for women in this category have been UCB's Evenity (romosozumab) or Eli Lilly's Forsteo (teriparatide), with older generic bisphosphonates such as alendronic acid used ...
Number 1: In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ...
Overall, 10 randomly selected women received teriparatide and the remaining 11 served as controls. Patients who received teriparatide had increased bone formation on both cancellous and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results